ABOS Stock Price
Acumen Pharmaceuticals, Inc.
ABOS stock price is $1.75 (-3.86% on the day), giving Acumen Pharmaceuticals, Inc. a market cap of $126.19M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
ABOS Stock Overview
- Price
- $1.75
- Previous close
- $1.81
- Open
- $1.81
- Market cap
- $126.19M
- P/E ratio
- -1.0
- 52-week range
- $1.50 - $3.60
- 1-year price target
- $7.75
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NGS
- MarketXLS Rank
- 31
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABOS | $1.75 | -3.9% | 619.66K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Acumen Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW